

**IN THE UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

NOVARTIS PHARMACEUTICALS
CORPORATION and DANA-FARBER
CANCER INSTITUTE, INC.,

Plaintiffs,

v.

DR. REDDY'S LABORATORIES, INC.
and DR. REDDY'S LABORATORIES, LTD.,

Defendants.

Civil Action No. _____

COMPLAINT

Novartis Pharmaceuticals Corporation ("Novartis") and Dana-Farber Cancer Institute, Inc. ("Dana-Farber") (collectively, "Plaintiffs") by its attorneys hereby allege as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, against defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (collectively, "DRL"). This action relates to Abbreviated New Drug Application ("ANDA") No. 215921 filed by DRL with the U.S. Food and Drug Administration ("FDA") for approval to engage in the commercial manufacture, use, offer for sale, or sale of a generic version of Novartis's RYDAPT® Capsules, 25 mg, prior to the expiration of U.S. Patent No. 7,973,031 (the "'031 Patent" or "Asserted Patent").

PARTIES

A. Plaintiffs

2. Plaintiff Novartis is a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at One Health Plaza, East Hanover, New Jersey 07936-1080.

3. Novartis is engaged in the business of creating, developing, and bringing to market revolutionary drug therapies to benefit patients against serious diseases, including treatments for leukemia and mastocytosis. RYDAPT® is one such treatment option. Novartis markets and sells RYDAPT® in this judicial district and throughout the United States.

4. Plaintiff Dana-Farber is a non-profit corporation organized and existing under the laws of the State of Massachusetts, having a principal place of business at 450 Brookline Avenue, Boston, Massachusetts 02215.

5. Dana-Farber is a world-renowned center for patient care, research and education. Dana-Farber helps to advance this mission through, among other things, licensing intellectual property which helps to fund innovative research and treatment for cancer and other patients who have sought treatment in their hospital and other facilities.

6. Novartis and Dana-Farber own all rights in the '031 Patent.

B. Defendant DRL

7. Upon information and belief, Defendant Dr. Reddy's Laboratories, Inc. is a corporation organized and existing under the laws of the State of New Jersey, having a principal place of business at 107 College Road East, Princeton, New Jersey 08540.

8. Upon information and belief, Defendant Dr. Reddy's Laboratories Ltd. is a corporation organized and existing under the laws of India, having a principal place of business at 8-2-377, Road No. 3, Banjara Hills, Hyderabad, 50034, India.

9. Upon information and belief, Dr. Reddy's Laboratories, Ltd. is in the business of, among other things, developing, manufacturing, and selling generic versions of branded pharmaceutical products for the U.S. market. Upon information and belief, Dr. Reddy's Laboratories, Inc. is a wholly-owned subsidiary of Dr. Reddy's Laboratories, Ltd. and is controlled and/or dominated by Dr. Reddy's Laboratories, Ltd. Upon information and belief, Dr. Reddy's Laboratories, Inc. develops, manufactures and/or distributes generic drug products for marketing, sale, and/or use throughout the United States, including in this judicial district, at the direction, under the control, and for the benefit of Dr. Reddy's Laboratories, Ltd.

10. Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. are collectively referred to hereafter as "DRL" unless otherwise noted.

DEFENDANTS' INFRINGING ACTS

11. By a letter dated June 16, 2021, DRL notified Plaintiffs that DRL had submitted to the FDA ANDA No. 215921 for a generic version of RYDAPT® (DRL's "ANDA Product"), seeking approval under the Federal Food, Drug, and Cosmetic Act ("FDCA") to engage in the commercial manufacture, use, offer for sale, and/or sale of DRL's ANDA Product prior to the expiration of the '031 Patent.

12. In its Notice Letter, DRL notified Plaintiffs that, as a part of its ANDA, DRL had filed a certification of the type described in Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), with respect to the '031 Patent asserting that the '031 Patent is invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, offer for sale, and sale of DRL's ANDA Product.

13. Upon information and belief, and consistent with their past practices, Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. acted collaboratively in the preparation and submission of ANDA No. 215921.

14. Upon information and belief, and consistent with their past practices, following any FDA approval of ANDA No. 215921, Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. will work in concert with one another to make, use, offer to sell, and/or sell the ANDA Product throughout the United States, and/or import such generic drug product into the United States, including in this judicial district.

15. DRL has committed an act of infringement in this judicial district by filing ANDA No. 215921 with the intent to make, use, offer to sell, and/or sell the generic drug products that are the subject of ANDA No. 215921 in this judicial district, an act of infringement that has led to foreseeable harm and injury to Novartis, a corporation having a principal place of business in New Jersey.

16. DRL has extensive contacts with the State of New Jersey, regularly conducts business in the State of New Jersey, either directly or through one or more of its wholly owned subsidiaries, agents, and/or alter egos, has purposefully availed itself of the privilege of doing business in the State of New Jersey, and intends to sell in the State of New Jersey the generic product described in ANDA No. 215921 upon approval. Furthermore, upon information and belief, DRL is incorporated in this judicial district and has a principal, regular, and established place of business in this judicial district.

17. Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. have availed themselves of the legal protections of the State of New Jersey by, among other things, admitting jurisdiction and asserting claims and counterclaims in lawsuits filed in the United States District

Court for the District of New Jersey. *See e.g., Dr. Reddy's Laboratories, Inc. et al. v. AstraZeneca AB et al.*, C.A. No. 18-16057 (D.N.J.); *Celgene Corporation v. Dr. Reddy's Laboratories, Ltd. et al.*, C.A. No. 21-02111 (D.N.J.); *Merck Sharp & Dohme BV et al v. Dr. Reddy's Laboratories, Inc. et al.*, C.A. No. 20-02909 (D.N.J.); *Mitsubishi Tanabe Pharma Corporation et al. v. Dr. Reddy's Laboratories, Inc. et al.*, 19-18764 (D.N.J.); *Bristol-Myers Squibb Company v. Dr. Reddy's Laboratories, Ltd. et al.*, C.A. No. 19-18686 (D.N.J.).

JURISDICTION AND VENUE

18. This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, *et seq.*, and this Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331 and 1338(a). Venue is proper in this Court under 28 U.S.C. §§ 1391 and 1400(b).

19. This Court has personal jurisdiction over DRL because, among other things, DRL has committed, or aided, abetted, contributed to, or participated in the commission of, tortious acts of patent infringement in filing its ANDA that has led to foreseeable harm and injury to Novartis, a corporation having a principal place of business in New Jersey.

20. This Court also has personal jurisdiction over DRL because of its affiliations with the State of New Jersey, including in many instances by virtue of its incorporation in New Jersey or the incorporation in New Jersey of subsidiaries, are so continuous and systematic as to render DRL essentially at home in this forum.

21. This Court also has personal jurisdiction over DRL because it has frequently availed itself of the legal protections of the State of New Jersey by, among other things, selecting the State of New Jersey as the place of incorporation for itself and their subsidiaries and admitting jurisdiction and filing lawsuits and asserting counterclaims in lawsuits filed in the United States District Court for the District of New Jersey.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.